ESTRELLA IMMUNOPHARMA INC (ESLA) Stock Price, Quote, News and Overview
NASDAQ:ESLA - Nasdaq - US2975841048 - Common Stock - Currency: USD
ESLA Quote, Performance and Key Statistics
NASDAQ:ESLA (4/24/2025, 8:05:40 PM)
0.96
-0.06 (-5.87%)
The current stock price of ESLA is 0.96 USD. In the past month the price decreased by -2.04%. In the past year, price decreased by -5.88%.
ESLA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.82 | 319.07B | ||
| AMGN | AMGEN INC | 14.12 | 150.46B | ||
| GILD | GILEAD SCIENCES INC | 13.71 | 132.33B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1698.17 | 126.60B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.14 | 65.57B | ||
| ARGX | ARGENX SE - ADR | 322.85 | 36.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.56B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.98B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.60B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 27.06B | ||
| NTRA | NATERA INC | N/A | 20.88B | ||
| BIIB | BIOGEN INC | 7.26 | 17.49B |
Related stock screener links
About ESLA
Company Profile
Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies for patients with cancers and autoimmune diseases. The company is headquartered in Emeryville, California. The company went IPO on 2021-07-19. The firm is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The firm is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The firm is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE).
Company Info
ESTRELLA IMMUNOPHARMA INC
5858 Horton St, Suite 370
Emeryville CALIFORNIA US
Employees: 0
Company Website: https://www.estrellabio.com/
Investor Relations: http://www.estrellabio.com/investors
Phone: 15103189098
ESTRELLA IMMUNOPHARMA INC / ESLA FAQ
What is the stock price of ESTRELLA IMMUNOPHARMA INC today?
The current stock price of ESLA is 0.96 USD. The price decreased by -5.87% in the last trading session.
What is the ticker symbol for ESTRELLA IMMUNOPHARMA INC stock?
The exchange symbol of ESTRELLA IMMUNOPHARMA INC is ESLA and it is listed on the Nasdaq exchange.
On which exchange is ESLA stock listed?
ESLA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ESTRELLA IMMUNOPHARMA INC stock?
7 analysts have analysed ESLA and the average price target is 16.32 USD. This implies a price increase of 1600% is expected in the next year compared to the current price of 0.96. Check the ESTRELLA IMMUNOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ESTRELLA IMMUNOPHARMA INC worth?
ESTRELLA IMMUNOPHARMA INC (ESLA) has a market capitalization of 34.73M USD. This makes ESLA a Nano Cap stock.
How many employees does ESTRELLA IMMUNOPHARMA INC have?
ESTRELLA IMMUNOPHARMA INC (ESLA) currently has 0 employees.
What are the support and resistance levels for ESTRELLA IMMUNOPHARMA INC (ESLA) stock?
ESTRELLA IMMUNOPHARMA INC (ESLA) has a support level at 0.8 and a resistance level at 1.02. Check the full technical report for a detailed analysis of ESLA support and resistance levels.
Should I buy ESTRELLA IMMUNOPHARMA INC (ESLA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ESLA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ESLA, evaluating the profitability, health, valuation and growth aspects
- ESTRELLA IMMUNOPHARMA INC (ESLA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ESTRELLA IMMUNOPHARMA INC (ESLA) Sales and EPS estimates to see what analysts future expectations are.
- ESTRELLA IMMUNOPHARMA INC (ESLA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ESTRELLA IMMUNOPHARMA INC (ESLA) Insider and Institutional Ownership to learn about the owners and their transactions.
- ESTRELLA IMMUNOPHARMA INC (ESLA) Stock Chart to make your own analysis
- ESTRELLA IMMUNOPHARMA INC (ESLA) Latest news and press-releases to stay up to date.
Does ESTRELLA IMMUNOPHARMA INC (ESLA) stock pay dividends?
ESLA does not pay a dividend.
What is the Price/Earnings (PE) ratio of ESTRELLA IMMUNOPHARMA INC (ESLA)?
ESTRELLA IMMUNOPHARMA INC (ESLA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.24).
What is the Short Interest ratio of ESTRELLA IMMUNOPHARMA INC (ESLA) stock?
The outstanding short interest for ESTRELLA IMMUNOPHARMA INC (ESLA) is 0.22% of its float. Check the ownership tab for more information on the ESLA short interest.
ESLA Technical Analysis
ESLA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ESLA. While ESLA seems to be doing ok healthwise, there are quite some concerns on its profitability.
ESLA Financial Highlights
Over the last trailing twelve months ESLA reported a non-GAAP Earnings per Share(EPS) of -0.24. The EPS increased by 87.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -236.08% | ||
| ROE | -1181.55% | ||
| Debt/Equity | 0 |
ESLA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ESLA. The Buy consensus is the average rating of analysts ratings from 7 analysts.